In cancer, including breast cancer, visfatin induces inflammation and immunosuppression, mainly through NF-kB regulation [136] as well as cell proliferation and apoptosis inhibition through AKT/PI3K and ERK/MAPK signaling [137]. Here, AKT1 is linked to breast carcinoma.